Company Performance Metrics
- Charles Askew: President and Co-Founder
NabGen, Inc. is an NC based biotech company developing an antibody suppression platform with broad applications. Their initial focus is solving a long-standing limitation in gene therapy: patient derived anti-drug antibodies that form a barrier to delivery of AAV based therapeutics. NabGen’s primary goal is to ensure all patients benefit from gene
therapy treatments by enabling successful administration to those with pre-existing vector immunity and generating redosing opportunities that are currently unavailable. Using a novel protein-based approach as a universal antibody suppressant, NabGen’s technology broadly targets and blocks all antibody types, including neutralizing antibodies (NAbs) against any therapeutic vector, thus enabling successful vector mediated gene delivery without immunocompromising patients.
